

ENGOT_OV50 / INNOVATE_3

Studie opzet & behandeling:

ENGOT-ov50/ INNOVATE-3 (EF-28)

randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer

Primair eindpunt: Overall survival (OS)

Aantal benodigde patiënten: 540 (enrollment period 30 months)

Deelnemende centra: AMC, Erasmus, MUMC, UMCU, Catharina?

Contact persoon / website: Ingrid Boere